Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.

ABSTRACT:

Background

The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern.

Methods

We reviewed our clinical experience with adoptive cellular CAR T-cell therapy at our institution since 2016 and ascertained the occurrence of second tumors. In one case of secondary T-cell lymphoma, a broad array of molecular, genetic, and cellular techniques were used to interrogate the tumor, the CAR T cells, and the normal hematopoietic cells in the patient.

Results

A total of 724 patients who had received T-cell therapies at our center were included in the study. A lethal T-cell lymphoma was identified in a patient who had received axicabtagene ciloleucel therapy for

SUBMITTER: Hamilton MP 

PROVIDER: S-EPMC11338600 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature